

## Sunday, November 4, 2007

**3:00 PM-9:00 PM Exhibits**  
Ballroom Foyer, Level 2

**7:00 PM-9:15 PM Opening Session**  
Ballroom 2, Level 2

### Welcome and Opening Remarks

**Edison T. Liu**, Genome Institute of Singapore, Singapore

**William N. Hait**, Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, NJ, USA

**Khaw Boon Wan**, Ministry of Health, Singapore

### Keynote Addresses

Applications of Biological Large Scale Integration to Cancer

**Stephen Quake**, Stanford University, Stanford, CA, USA

New Results in Susceptibility to Breast Cancer and Their Implications\*

**Bruce A. J. Ponder**, Cancer Research UK Cambridge Research Institute, Cambridge, England

**9:15 PM-10:30 PM Opening Reception**  
Ballroom Foyer, Level 2

## Monday, November 5, 2007

**8:00 AM-7:30 PM Exhibits**  
Ballroom Foyer, Level 2

**9:00 AM-11:30 AM Plenary Session 1: Frontier Technologies**  
Ballroom 2, Level 2

**Co-Chairpersons:** **Lance D. Miller**, Genome Institute of Singapore, Singapore; **Patrick B. Tan**, National Cancer Centre, Singapore

Whole Genome Chromatin Interaction Analysis of Transcriptional Regulation Networks in Human Cancer Cells\*

**Yijun Ruan**, Genome Institute of Singapore, Singapore

A Systems Approach to Marker Guided Therapy in Breast Cancer

**Joe W. Gray**, Lawrence Berkeley National Laboratory, Berkeley, CA, USA

Nanostructure Processing of Advanced Biomaterials and Biosystems\*

**Jackie Yi-Ru Ying**, Institute for Bioengineering and Nanotechnology, Singapore

Righting the Cancer Epigenome by Epigenetic Therapy

**Peter A. Jones**, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA

**11:30 AM-1:00 PM Poster Session A**  
Ballroom 1, Level 2

**1:00 PM-3:30 PM Plenary Session 2: Proteomics, Genomics, and Novel Therapeutics**  
Ballroom 2, Level 2

**Co-Chairpersons:** **Hew Choy Leong** and **John Wong**, National University of Singapore, Singapore

Plasma Biomarker Analysis via High Sensitivity, Targeted Analysis of *N-glycosites*

**Rudolf Hans Aebersold**, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology, Zürich, Switzerland

Drugging "Undruggable" Targets in Cancer\*

**Gregory L. Verdine**, Harvard University, Cambridge, MA, USA

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Innovation and Cost-effectiveness of Cancer Therapy in the Systems Biomedicine Era

**Zhu Chen**, Ministry of Health, Beijing, China

Breakthroughs in Cancer Biomarker Discovery Using Innovative Strategies

**Samir M. Hanash**, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Patterns of Somatic Mutation in Human Cancer Genomes\*

**Michael R. Stratton**, Wellcome Trust Sanger Institute, Cambridge, England

**3:30 PM-4:00 PM Refreshment Break**  
Ballroom Foyer, Level 2

**4:00 PM-5:30 PM Panel Discussion:  
Culture, Policy, and Economics of Cancer Research and Cancer Care—A Global Perspective**  
Ballroom 2, Level 2

**Moderator: Edison T. Liu**, Genome Institute of Singapore, Singapore

**Panelists:**

**William N. Hait**, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA

**Ying-I Yong**, Ministry of Health, Singapore

**Zhu Chen**, Ministry of Health, Beijing, China

**James H. Doroshow**, National Cancer Institute, Bethesda, MD, USA

**5:30 PM-7:30 PM Poster Session A (continued)**  
Ballroom 1, Level 2

## Tuesday, November 6, 2007

**8:00 AM-7:30 PM Exhibits**  
Ballroom Foyer, Level 2

**9:00 AM-11:30 AM Plenary Session 3:  
Animal Systems and Imaging in Cancer Research**  
Ballroom 2, Level 2

**Co-Chairpersons: Huynh Hung**, National Cancer Centre, Singapore; **Philip Ingham**, Institute of Molecular and Cell Biology, Singapore

Harnessing Transposons for Cancer Gene Discovery  
**Nancy A. Jenkins**, Institute of Molecular and Cell Biology, Singapore

Genetic Screens for Potential Leukemia Stem Cell Maintenance Genes  
**Neal G. Copeland**, Institute of Molecular and Cell Biology, Singapore

Role of Polycomb Repressors in Stem Cells, Cancer, and Development\*  
**Maarten van Lohuizen**, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Targeting the Notch Pathway in Cancer\*  
**A. Thomas Look**, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Dissecting Signal Transduction Pathways *In vivo* with Dynamic Real-time Molecular Imaging\*  
**David Piwnica-Worms**, Washington University School of Medicine, St. Louis, MO, USA

**11:30 AM-1:00 PM Poster Session B**  
Ballroom 1, Level 2

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**1:00 PM-3:00 PM    Plenary Session 4:  
New Trials and  
Genomic-Based Design**  
Ballroom 2, Level 2

**Co-Chairpersons:** **Tan Say Beng**, Clinical Trials and Epidemiology Research Unit, Singapore; **Soo Kee Chee**, National Cancer Centre, Singapore

Phase 0 Clinical Trials from Concept to Practice  
**James H. Doroshow**, National Cancer Institute, Bethesda, MD, USA

Design of Clinical Trials of Targeted Therapy\*  
**Stephen L. George**, Duke University Medical Center, Durham, NC, USA

Genomic Strategies for Personalized Cancer Therapy\*  
**Joseph R. Nevins**, Duke Institute for Genome Sciences & Policy, Durham, NC, USA

Discovery of Recurrent Gene Fusions in Prostate Cancer: A New Class of Biomarkers and Therapeutic Targets\*  
**Arul M. Chinnaiyan**, University of Michigan Medical School, Ann Arbor, MI, USA

**3:00 PM-3:30 PM    Refreshment Break**  
Ballroom Foyer, Level 2

**3:30 PM-5:30 PM    Concurrent Session 1:  
Clinical Pharmacogenetics:  
Assessing Global Diversity**  
Meeting Room 301-302, Level 3

**Co-Chairpersons:** **John C. W. Lim**, Health Sciences Authority, Singapore; **Tan Hang Chong**, National Cancer Centre, Singapore

Unbiased Cell-Based Models to Identify Genetic Variants Associated with Chemotherapeutic Induced Toxicity\*  
**M. Eileen Dolan**, University of Chicago, Chicago, IL, USA

Ethnicity and Pharmacogenetics of Anticancer Therapy\*  
**Boon Cher Goh**, Yong Loo Lin School of Medicine, Singapore

Personalized Chemotherapy: The Case for Pharmacogenetics  
**Pui-Yan Kwok**, University of California, San Francisco, San Francisco, CA, USA

Pharmacogenetics: Views from the Pharmaceutical Industry\*  
**Eric H. Lai**, GlaxoSmithKline, Research Triangle Park, NC, USA

**3:30 PM-5:30 PM    Concurrent Session 2:  
Ultra-High Throughput  
Sequencing Technologies:  
Towards Patient Genome  
Sequencing**  
Meeting Room 303-305, Level 3

**Co-Chairpersons:** **Yijun Ruan** and **Chia Lin Wei**, Genome Institute of Singapore, Singapore

The Future is Now: Single Molecule DNA Sequencing  
**Stephen Quake**, Stanford University, Stanford, CA, USA

Applications of Ultra-High Throughput Sequencing  
**Michael Egholm**, 454 Life Sciences, Branford, CT, USA

Enabling Key Applications with the SOLiD™ System\*  
**Robert Nutter**, Applied Biosystems, Foster City, CA, USA

Enabling Genome Biology with Solexa Next Generation Sequencing Technology  
**Gary P. Schroth**, Illumina, Inc, Hayward, CA, USA

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**3:30 PM-5:30 PM      Concurrent Session 3:  
Hereditary Cancers**  
Meeting Room 325-326, Level 3

**Co-Chairpersons:** Ivy Ng, KK Women's and Children's Hospital, Singapore; **Kon Oi Lian**, National Cancer Centre, Singapore

Identification of Host Genetic Factors Important for Breast Cancer Susceptibility and Prognosis

**Edison T. Liu** and **Jian-Jun Liu**, Genome Institute of Singapore, Singapore

The Discovery and Validation of Biomarkers that Predict Response to Novel Cancer Therapeutics  
**Richard Wooster**, GlaxoSmithKline, Narbeth, PA, USA

Using Genetics to Individualize Therapy in Breast Cancer  
**Olufunmilayo I. Olopade**, University of Chicago Medical Center, Chicago, IL, USA

Recent Advances in Familial Colorectal Cancer Genetics and Diagnostics\*  
**Peh Yean Cheah**, Singapore General Hospital, Singapore

**5:30 PM-7:30 PM      Poster Session B (continued)**  
Ballroom 1, Level 2

**Wednesday, November 7, 2007**

**8:00 AM-7:30 PM      Exhibits**  
Ballroom Foyer, Level 2

**9:00 AM-11:30 AM      Plenary Session 5:  
Cancer Stem Cells**  
Ballroom 2, Level 2

**Co-Chairpersons:** Alan Coleman, Institute of Medical Biology, Singapore; **Ng Huck Hui**, National University of Singapore, Singapore

Cellular Genomics  
**Spyro Mousses**, TGen, Scottsdale, AZ, USA

Breast Stem Cells and Their Implications for Cancer\*  
**Jane Visvader**, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Leukemia Stem Cells in CML: Characterization and Elimination\*  
**Joanne C. Mountford**, University of Glasgow, Glasgow, Scotland

Effect of Oncogenes on Embryonic Stem Cells  
**Bing Lim**, Genome Institute of Singapore, Singapore

**11:30 AM-1:00 PM      Poster Session C**  
Ballroom 1, Level 2

**1:00 PM-3:00 PM      Plenary Session 6:  
Clinical Intervention and  
Populations Outcomes:  
Global Strategies**  
Ballroom 2, Level 2

**Co-Chairpersons:** Chia Kee Seng, National University of Singapore, Singapore; **Chien Earn Lee**, Ministry of Health, Singapore

Normalization of Tumor Vasculature and Microenvironment by Antiangiogenic Therapies: From the Bench to Bedside and Back\*  
**Rakesh K. Jain**, Massachusetts General Hospital, Boston, MA, USA

Role of Anti-EGFR Therapy in Asian Cancer Patients\*  
**Yung-Jue Bang**, Seoul National University College of Medicine, Seoul, Republic of Korea

Early Detection Is the Key to Improving Survival in Gastric Cancer  
**Khay-Guan Yeoh**, National University of Singapore, Singapore

HPV Vaccine Development  
**Douglas R. Lowy**, National Cancer Institute, NIH, Bethesda, MD, USA

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**3:00 PM-3:30 PM Refreshment Break**  
Ballroom Foyer, Level 2

**3:30 PM-5:30 PM Concurrent Session 4: Cancer Prevention**  
Meeting Room 301-302, Level 3

**Chairperson: Mabel Yap**, Ministry of Health, Singapore

Preventing Colorectal Neoplasia Methods: Means and Myths\*

**John D. Potter**, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Diverse Mechanisms of Carcinogenesis by RUNX Gene Family

**Yoshiaki Ito**, Institute of Molecular and Cell Biology, Singapore

Cyclin D1 as a Target for Cancer Chemoprevention\*

**Ethan Dmitrovsky**, Dartmouth Medical School, Hanover, NH, USA

Global Cancer Control: One Size Fits Very Little

**Peter Boyle**, International Agency for Research on Cancer, Lyon, France

**3:30 PM-5:30 PM Concurrent Session 5: Advances in Cancer Therapeutics**  
Meeting Room 303-305, Level 3

**Co-Chairpersons: Toh Eng Huat**, National University of Singapore, Singapore; **Mickey Koh**, Singapore General Hospital, Singapore

Adoptive Immunotherapy with Zinc Finger Nuclease Engineered T Cells

**Carl H. June**, University of Pennsylvania, Philadelphia, PA, USA

How to Explore PHY906, a Chinese Medicine Formula, as Adjuvant Therapy for Cancer

**Yung-chi Cheng**, Yale University School of Medicine, New Haven, CT, USA

When will Molecular Fingerprints Dominate Cancer Treatment Selection?\*

**Martine J. Piccart-Gebhart**, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium

Clinical and Translational Studies with MEK Inhibitors

**Alex A. Adjei**, Roswell Park Cancer Institute, Buffalo, NY, USA

**3:30 PM-5:30 PM Concurrent Session 6: Systems Medicine**  
Meeting Room 325-326, Level 3

**Co-Chairperson: Edison T. Liu**, Genome Institute of Singapore, Singapore; **Patrick J. Casey**, Duke University Medical Center, Durham, NC, USA

Title to be announced

**Chi Van Dang**, Johns Hopkins University School of Medicine, Baltimore, MD, USA

A PK/PD and Systems Biology Approach for Anti-angiogenic Drug Discovery\*

**Jonathan M. Yingling**, Eli Lilly and Company, Indianapolis, IN, USA

A Robustness-based Approach to Systems-oriented Drug Design\*

**Hiroaki Kitano**, The Systems Biology Institute, Tokyo, Japan

Genomic and Epigenomic Profiling in Cancer\*

**Hiroyuki Aburatani**, University of Tokyo, Tokyo, Japan

**5:30 PM-7:30 PM Poster Session C (continued)**  
Ballroom 1, Level 2

**8:00 PM-10:00 PM Conference Banquet**  
Raffles Ballroom,  
Swissotel The Stamford

All conference registrants are invited to attend.

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

## Thursday, November 8, 2007

**8:00 AM-9:00 AM**    **Special Session**  
**Late-Breaking Abstract in**  
**Translational and Clinical**  
**Cancer Medicine**  
 Ballroom 2, Level 2

**Co-Chairpersons:** **Edison T. Liu**, Genome Institute of Singapore, Singapore; **William N. Hait**, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA

LB-01 A phase II clinical trial of melanoma tumor-lysate-pulsed autologous dendritic cell vaccination in advanced colorectal cancer patients expressing the MAGE family antigen/s.

**Toh Han Chong**, National Cancer Centre, Singapore

LB-02 Early prediction of anti-epidermal growth factor receptor therapy with 18[F]FDG-PET: A preclinical and clinical correlation

**Wen W. Ma**, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

LB-03 A58 Genetic polymorphisms and minimal residual disease in childhood acute lymphoblastic leukemia: Malaysia-Singapore (Ma-Spore)

ALL 2003 study

**Shirley Kow Yin Kham**, National University of Singapore, Singapore

Additional speaker to be announced

**9:15 AM-11:45 AM**    **Plenary Session 7:**  
**Target to Lead: New**  
**Strategies in Drug**  
**Development**  
 Ballroom 2, Level 2

**Co-Chairpersons:** **David M. Virshup**, Duke-NUS Graduate Medical School, Singapore; **Jeanette Wood**, S\*Bio, Singapore

Drug Discovery in the p53 Pathway

**David P. Lane**, Institute of Molecular and Cell Biology, Singapore

From Cancer Genomics to Cancer Treatment\*

**Yusuke Nakamura**, University of Tokyo, Tokyo, Japan

Targeting Epigenetic Process for Therapeutic Control of Wnt/ $\beta$ -catenin Signaling in Colorectal Cancer\*

**Qiang Yu**, Genome Institute of Singapore, Singapore

Functional and Prognostic Insights into the Altered Cancer Genome\*

**Lance D. Miller**, Genome Institute of Singapore, Singapore

**11:45 AM-12:00 PM**    **Closing Session:**  
**Concluding Remarks**  
 Ballroom 2, Level 2

**Edison T. Liu**, Genome Institute of Singapore, Singapore

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.